Immunocore Limited

Medigene, Inc.

Adaptimmune Limited

Meir Glick

Bent Karsten Jakobsen

The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCR &#x3b1; chain, except the transmembrane domain thereof, and (ii) all or part of a TCR &#x3b2; chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR.

Soluble T cell receptors

The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCR $g(a) chain, except the transmembrane domain thereof, and (ii) all or part of a TCR $g(b) chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR, characterized in that the sTCR recognizes a CD1-antigen complex, a bacterial superantigen or a peptide-MHC/superantigen complex.

Modified soluble T cell receptor

A single chain T cell receptor (scTCR) comprising an a segment constituted by a TCR &#x3b1; chain variable region sequence fused to the N terminus of a TCR &#x3b1; chain constant region extracellular sequence, a &#x3b2; segment constituted by a TCR &#x3b2; chain variable region fused to the N terminus of a TCR &#x3b2; chain constant region extracellular sequence, and a linker sequence linking the C terminus of the &#x3b1; segment to the N terminus of the &#x3b2; segment, or vice versa, the constant region extracellular sequences of the &#x3b1; and &#x3b2; segments being linked by a disulfide bond, the length of the linker sequence and the position of the disulfide bond being such that the variable region sequences of the &#x3b1; and &#x3b2; segments are mutually orientated substantially as in native &#x3b1;&#x3b2; T cell receptors. Complexes of two or more such scTCRs, and use of the scTCRs in therapy and in various screening applications are also disclosed.

Single chain recombinant T cell receptors

The present invention provides modified CD8 molecules whose binding to MHC is enhanced compared to wild-type CD8, wherein Serof at least one CD8&#x3b1; chain thereof is mutated to another amino acid. It also provides nucleic acids encoding such molecules and methods of using such molecules and nucleic acids in immunosuppressive therapy, in particular as inhibitors of cytotoxic T cell responses.

CD8alpha mutants

The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all for part of a TCR &#x3b1; chain, except the transmembrane domain thereof, and (ii) all or part of a TCR &#x3b2; chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR.

Growing community of inventors

Stoughton, MA, United States of America

Meir Glick